Outcome of plasmapheresis in myasthenia gravis: Delayed therapy is not favorable

Muscle and Nerve

Volumn 43, Issue 4, 2011, Pages 578-584

  Mandawat, Aditya ^a   Mandawat, Anant ^b   Kaminski, Henry J ^c   Shaker, Zaid A ^c   Alawi, Aws A ^c   Alshekhlee, Amer ^a,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complications; Initiation; Mortality; Myasthenia gravis; Plasma exchange; Plasmapheresis

Indexed keywords

ARTICLE; HOSPITAL ADMISSION; MORTALITY; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT OUTCOME; AGED; COHORT ANALYSIS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; HOSPITAL DISCHARGE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; STANDARDS; TIME; TRENDS;

AGED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PATIENT DISCHARGE; PLASMAPHERESIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953054038     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21924     Document Type: Article

References (26)

1. El-Bawab H, Hajjar W, Rafay M, Bamousa A, Khalil A, Al-Kattan K. Plasmapheresis before thymectomy in myasthenia gravis: routine versus selective protocols. Eur J Cardiothorac Surg 2009;35:392-397.
2. Trikha I, Singh S, Goyal V, Shukla G, Bhasin R, Behari M. Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial. J Neurol 2007;254:989-995. (Pubitemid 47353400)
3. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apheresis 2007;22:106-175. (Pubitemid 47025120)
4. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008;CD002277.
5. Assessment of plasmapheresis. Neurology 1996;47:840-843.
6. Tesa V, Jelínková, E, Jirsa M Jr, Bakosová M, Piha, P, Chábová V. Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange. Blood Purif 2000;18:115-120. (Pubitemid 30619146)
7. Yeh JH, Chen WH, Chiu HC, Bai CH. MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis. J Neurol Sci 2007;263:191-193.
8. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997;41:789-796. (Pubitemid 27249184)
9. Qureshi AI, Choudhry MA, Akbar MS, Mohammed Y, Chua HC, Yahia AM, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52:629-632. (Pubitemid 29075617)
10. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283:2941-2947. (Pubitemid 30414505)
11. Nallamothu BK, Bates ER, Herrin J, Wang Y, Bradley EH, Krumholz HM. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005;111:761-767. (Pubitemid 40250637)
12. Charlson ME, Pompei P, Ales KA, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383. (Pubitemid 17055592)
13. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-1139. (Pubitemid 41587600)
14. Hardy MA, Bryman A. Handbook of data analysis. London: Sage; 2004.
15. Cohen J. Applied multiple regression/correlation analysis for the behavioral sciences, 3rd ed. Mahwah, NJ: Erlbaum; 2003.
16. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
17. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
18. Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc 1996;91:473-489.
19. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8:3-15. (Pubitemid 29222784)
20. Raghunathan TE. What do we do with missing data? Some options for analysis of incomplete data. Annu Rev Public Health 2004;25:99-117. (Pubitemid 38543612)
21. Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, et al. Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci 1991;106:213-220.
22. Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 2009;66:1334-1338.
23. Hofstad H, Ohm O-J, Mørk SJ, Aarli JA. Heart disease in myasthenia gravis. Acta Neurol Scand 1984;70:176-184. (Pubitemid 14043469)
24. Rodnitzky RL, Goeken JA. Complications of plasma exchange in neurological patients. Arch Neurol 1982;39:350-354. (Pubitemid 12109206)
25. Aarli JA. Herzmyasthenie: myasthenia of the heart. Arch Neurol 2009;66:1322-1323.
26. Madore F, Lazarus J, Brady H. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996;7:367-386. (Pubitemid 26128308)